Professor, Surgery and Radiology, and Affiliate Faculty, Institute for Health Policy Studies, UCSF
Member, Program in Biological and Medical Informatics (BMI)
Director, Carol Franc Buck Breast Care Center; Co-Leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
| CONTACT | |
|
(415) 353-7111 (appts) Box 1710, UCSF; San Francisco, CA 94143-1710 |
additional websites: |
| EDUCATION | |
|
Harvard University, A.B., 1977, History of Science
|
|
| PROFESSIONAL EXPERIENCE | |
|
1985-1988 |
Postdoctoral Fellow, Dept. of Medicine, Division of Oncology, Stanford University School of Medicine |
|
1988-1990/1983-1985 |
Resident in General Surgery, Stanford University School of Medicine |
|
1990-1991 |
Chief Resident in General Surgery, Stanford University School of Medicine |
|
1991-1993 |
Consultant, Stanford University Hospital, Cost Benefit Issues in the ICU |
|
1992-1993 |
Staff General Surgeon, Palo Alto VeteranOs Administration |
|
1991-1993 |
Trauma Surgeon, Santa Clara Valley Medical Center |
|
06/92-8/93 |
Clinical Assistant Professor of Surgery, Stanford University Department of Surgery |
|
09/93-present |
Co-Director, Carol Franc Buck Breast Care Center, UCSF/Mount Zion Cancer Center, San Francisco, CA |
|
09/93-5/04 |
Assistant Professor of Surgery, UCSF/Mount Zion Medical Center |
|
06/96-present |
Affiliate Faculty, Institute for Health Policy Studies, University of California, San Francisco, CA |
|
07/96-present |
Co-Director, High-Risk Program for Breast and Ovarian Cancer, UCSF/Mount Zion Cancer Center, San Francisco, CA |
|
04/97-present |
Joint Appointment, Department of Radiology, University of California, San Francisco, CA |
|
06/97-present |
Executive Committee, Integrative Medicine Program, UCSF/Mount Zion Cancer Center, San Francisco, CA, Associate Professor, Surgery & Radiology |
|
07/97-present |
Director, UCSF Carol Franc Buck Breast Care Center, UCSF Helen Diller Family Comprehensive Cancer Center at Mt. Zion, San Francisco, CA |
|
06/98-present |
Clinical Program Leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center at Mt. Zion, San Francisco, CA |
|
6/04-present |
Professor of Surgery and Radiology, UCSF/Mount Zion Medical Center |
| HONORS & AWARDS | |
|
1974 |
Harvard University-Sophomore Standing |
|
1975 |
Harvard University-Susan B. Anthony Potter Prize |
|
1977 |
Harvard University-Magna Cum Laude |
|
1974, 1975, 1977 |
John J. Fomon Research Fellowship (American Cancer Society) |
|
1988-2002 |
Katherine McCormick Award |
|
1992,1993 |
Hartford Fellowship in Health Policy |
|
1991-1993 |
NFME Award (National Foundation for Medical Education) |
|
1999 |
UCSF Chancellor's Award for the Advancement of Women, Research Most Likely to Change Breast Cancer Management: Honorable Mention, BCRP |
|
1998, 99, 00, 01, 03 |
Breast Cancer Research Foundation Award |
| SELECTED PUBLICATIONS | |
|
Kuerer HM, Hwang ES, Anthony JP, Dudley RA, Crawford B, Aubry WM, and Esserman LJ. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. Annals of Surgical Oncology 7(5): 325-32, 2000. |
|
|
Esserman LJ, Wolverton, Hylton N. Integration of breast imaging into cancer management. Curr Oncol Rep. 2000 Nov;2(6):572-81. |
|
|
Esserman L and Crawford B. Hormone suppression may be the key to reducing beast cancer risk in BRCA1 and BRCA2 carriers. Abstracts in Hematology & Oncology Vol. 3, No. 1, Winter 2000. |
|
|
Mukherjee S, Louie SG, Campbell M, Esserman L, and Shyamala G. Ductal growth is impeded in mammary glands of C-neu transgenic mice. Oncogene 19(52): 5982-7, 2000. |
|
|
Esserman LJ, Wolverton D, Hylton N. Integration of breast imaging into cancer management. Curr Oncol Rep 2(6): 572-81, 2000. |
|
|
Burnside E, Belkora J, Esserman LJ. The impact of alternative practices on the cost and quality of mammographic screening in the United States. Clinical Breast Cancer 2(2):145-152, 2001. |
|
|
Esserman L. Using magnetic resonance imaging to assess response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Diseases: A Year Book Quarterly. 12(1): 19-20, 2001. |
|
|
Dooley W, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DA, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmidt PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, and King EB. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J of Natl Cancer Inst. 93(21):1624-32, 2001. |
|
|
Esserman LJ, Aubry W, Ziegler J, and Crawford B. Insurance issues in genetic testing for cancer: summary of a workshop. Managed Care and Cancer 3(1): 12-18, 2001. |
|
|
Esserman, LJ. Managed care and cancer interviews. Managed Care and Cancer 3(1): 38-41, 2001. |
|
|
Haas J, Kaplan C, McMillan A, Esserman LJ. Does timely assessment affect the anxiety associated with an abnormal mammogram result? Journal of Women's Health and Gender Based Management 10(6):599-605, 2001. |
|
|
Esserman LJ, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in Stage III breast cancer. Ann Surg Oncol. 2001 Jul;8(6):549-59. |
|
|
Esserman, L. Study Highlights Necessity for Developing Methods to Predict Benefit of SERMs in Reducing Breast Cancer Risk. Abstracts in Hematology and Oncology 4(4): Fall, 2001. |
|
|
Euhus DM, Smith KC, Robinson L, Stukey A, Olopade AI, Cummings S, Garber JE, Chitendon A, Mills GB, Reiger P, Esserman L, Crawford B, Hughes KS, Roche C, Ganz P, Seldon J, Fabian CJ, Klemp J, and Tomlinson G. Pretest Prediction of BRCA1 or BRCA2 Mutation by Risk Counselors and the Computer Model BRCAPRO. J Natl Cancer Inst. 5;94(11):844-51, 2002. |
|
|
Foster RD, Esserman L, Anthony JP, Hwang ES, Do H. Skin-Sparing Mastectomy and Immediate Breast Reconstruction: A Prospective Cohort Study for the Treatment of Advanced Stages of Breast Carcinoma. Ann. Surg. Oncology. 9(5):462-6, 2002. |
|
|
Esserman L, Cowley H, Eberle C, Kirkpatrick A, Chang S, Berbaum K, Gale A. Improving the the Accuracy of Mammography: Volume and Outcome Relationships. J Natl Cancer Inst. 2002 Mar 6;94(5):369-75. |
|
|
Esserman LJ. New Approaches to the Imaging Diagnosis, and Biopsy of Breast Legions. The Cancer Journal 2002 May/June;8 Suppl 1:S1-14. |
|
|
Esserman L, Wolverton D, Hylton N. Magnetic resonance imaging for primary breast cancer management: current role and new applications. Endocrine-Related Cancer, 2002 Jun;9 (2):141-153. |
|
|
Sepucha KR, Belkora JK, Mutchnick S, Esserman LJ. Consultation planning to help breast cancer patients prepare for medical consultations: effect on communication and satisfaction for patients and physicians. J Clin. Oncol. 2002 Jun 1;20 (11):2695-700. |
|
|
Jabrane-Ferrat N, Nekrep N, Giovanna T, Esserman LJ, Peterlin BM. Major Histocompatibility Complex Class II Transcriptional Platform: Assembly of Nuclear Factor Y and Regulatory Factor X (RFX) on DNA Requires RFX5 Dimers. Molecular and Cellular Biology, Aug. 2002. |
|
|
Wu CT, Morita ET, Treseler PA, Esserman LJ, Hwang ES, Kuerer HM, Santos CL, Leong SPL Failure to Harvest Sentinel Lymph Nodes Identified by Preoperative Lymphosicntigraphy in Breast Cancer Patients. The Breast Journal, 9(2):86-91, 2003. |
|
|
Sepucha KR, Belkora JK, Aviv C, Mutchnik S, Esserman LJ. Improving the quality of decision making in breast cancer: consultation planning template and consultation recording template. Oncol Nurs Forum, Jan-Feb; 30(1):99-106, 2003. |
|
|
Jabrane-Ferrat N, Nekrep N, Giovanna T, Esserman LJ, Peterlin BM. MHC class II enhanceosome: how is the class II transactivator recruited to DNA=bound activators? International Immunology, April 15(4): 467-475, 2003. |
|
|
2/1/05 |
|
